Business Standard

Sun Pharma posts net loss of Rs 2,277 cr in Q4, declares Rs 3 dividend

Sun Pharma's consolidated revenue rose 10% to Rs 9,446 cr in Q4FY22

Sun Pharma
Premium

BS Web Team New Delhi
Pharma major Sun Pharma on Monday reported a surprise consolidated net loss of Rs 2,277 crore for the quarter ending March 31, 2022. It reported consolidated net profit of Rs 848 crore in the year-ago period.

Total loss cited as an exceptional item during the fourth quarter, stood at Rs 3,936 crore. During the quarter and year ended March 2022, the company said its unit Taro Pharmaceutical Industries has acquired Alchemee, formerly The Proactiv Company (TPC), from Galderma. Accordingly, the results for the quarter and year ended March 2022 are not comparable to the earlier periods presented, it added.

Sun Pharma's consolidated

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 30 2022 | 4:11 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com